journal article·2017-05-23Open access

Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles

Kaili Hu, Lei Miao, Tyler J. Goodwin, Jun Li, Qi Liu, Leaf Huang

ACS Nano· Volume 11· Issue 5

Abstract

Our previous work demonstrated that Wnt16 expression in cisplatin-damaged tumor-associated fibroblasts is a key factor contributing to cisplatin resistance in malignancies. Natural antifibrotic compounds with low toxicities are promising candidates to downregulate Wnt16 expression, improving the antitumor effect of cisplatin nanoparticles. Upon screening several natural chemicals, we found that a dietary flavonoid, quercetin, significantly suppresses Wnt16 expression in activated fibroblasts. To facilitate drug delivery, we have prepared a targeted lipid/calcium/phosphate nanoparticle formulation consisting of a prodrug of quercetin, i.e., quercetin phosphate, with a high loading efficiency (26.6% w/w). This quercetin nanoparticle with a particle size of around 35 nm significantly improved the bioavailability and metabolic stability of the parent quercetin. Quercetin phosphate is released from the nanoparticles and converted back to the parent quercetin under physiological conditions. Following systemic administration of quercetin phosphate nanoparticles, a significant downregulation in Wnt16 expression was observed and further yielded a synergistic antitumor effect with cisplatin nanoparticles in a stroma-rich bladder carcinoma model. The α-SMA-positive fibroblast and collagen within the tumor decreased significantly after combination treatment. This suggests that the remodeling of the tumor microenvironment induced by quercetin plays a critical role in promoting the synergy. Indeed, our data further confirmed that quercetin phosphate alone significantly remodeled the tumor microenvironment and increased the penetration of second-wave nanoparticles into the tumor nests. Collectively, quercetin phosphate nanoparticles may be a safe and effective way to improve therapeutic treatment for desmoplastic tumors.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Wnt/β-catenin signaling in development and cancer · Protein Tyrosine Phosphatases · Fibroblast Growth Factor Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Division of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States

Murad Research Center for Modernized Chinese Medicine, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People’s Republic of China

Funding

National Cancer Institute · National Institute of Diabetes and Digestive and Kidney Diseases · Science and Technology Commission of Shanghai Municipality · State Key Laboratory of Molecular Engineering of Polymers, Fudan University

References (52)

Show source-provided references
1. 10.1016/j.drup.2012.01.00610.1016/j.drup.2012.01.006 ↗
2. 10.1021/nn404083m10.1021/nn404083m ↗
3. 10.1016/j.cell.2010.09.04310.1016/j.cell.2010.09.043 ↗
4. 10.1093/jnci/djm13510.1093/jnci/djm135 ↗
5. 10.1073/pnas.101889210810.1073/pnas.1018892108 ↗
6. 10.1038/nm.289010.1038/nm.2890 ↗
7. 10.1038/emboj.2012.12410.1038/emboj.2012.124 ↗
8. 10.1016/j.jconrel.2015.08.02710.1016/j.jconrel.2015.08.027 ↗
9. 10.1016/j.jep.2009.01.03510.1016/j.jep.2009.01.035 ↗
10. 10.1111/j.1440-1746.2006.04361.x10.1111/j.1440-1746.2006.04361.x ↗
11. 10.3748/wjg.v8.i4.67910.3748/wjg.v8.i4.679 ↗
12. 10.1038/srep2396810.1038/srep23968 ↗
13. 10.1146/annurev.nutr.21.1.38110.1146/annurev.nutr.21.1.381 ↗
14. 10.1016/j.canlet.2008.03.04610.1016/j.canlet.2008.03.046 ↗
15. 10.1016/S0304-3835(97)00261-910.1016/S0304-3835(97)00261-9 ↗
16. 10.1016/j.fct.2006.12.00210.1016/j.fct.2006.12.002 ↗
17. 10.1039/c3nr04651f10.1039/c3nr04651f ↗
18. 10.1039/c2nr32181e10.1039/c2nr32181e ↗
19. 10.1158/1078-0432.CCR-05-236510.1158/1078-0432.CCR-05-2365 ↗
20. Senter P. D. · Cancer Res. · 1989 · 49 · 5789
21. 10.1021/jm990617v10.1021/jm990617v ↗
22. 10.1016/j.semcancer.2015.02.00610.1016/j.semcancer.2015.02.006 ↗
23. 10.1016/j.bcp.2007.02.01410.1016/j.bcp.2007.02.014 ↗
24. 10.1093/carcin/bgh05210.1093/carcin/bgh052 ↗
25. 10.1016/j.freeradbiomed.2007.02.01710.1016/j.freeradbiomed.2007.02.017 ↗
26. 10.1111/febs.1320610.1111/febs.13206 ↗
27. 10.1002/mc.2231810.1002/mc.22318 ↗
28. 10.1016/j.jnutbio.2014.06.00810.1016/j.jnutbio.2014.06.008 ↗
29. 10.4161/auto.7.9.1586310.4161/auto.7.9.15863 ↗
30. 10.1215/15228517-2008-08510.1215/15228517-2008-085 ↗
31. 10.1016/j.bbrc.2004.12.15110.1016/j.bbrc.2004.12.151 ↗
32. 10.3892/ijo.2013.203610.3892/ijo.2013.2036 ↗
33. 10.1097/MJT.000000000000039210.1097/MJT.0000000000000392 ↗
34. 10.1038/srep0900310.1038/srep09003 ↗
35. 10.1016/j.biomaterials.2014.10.05710.1016/j.biomaterials.2014.10.057 ↗
36. 10.1021/nn405155b10.1021/nn405155b ↗
37. 10.1039/C5NR08966B10.1039/C5NR08966B ↗
38. Bates R. J. · J. Urol. · 1982 · 127 · 57410.1016/S0022-5347(17)53915-4 ↗
39. 10.1002/1097-0142(19810915)48:6<1455::AID-CNCR2820480630>3.0.CO;2-X10.1002/1097-0142(19810915)48:6<1455::AID-CNCR2820480630>3.0.CO;2-X ↗
40. 10.1126/science.106581710.1126/science.1065817 ↗
41. 10.1016/S0140-6736(01)06385-110.1016/S0140-6736(01)06385-1 ↗
42. 10.1016/j.jnutbio.2014.11.01710.1016/j.jnutbio.2014.11.017 ↗
43. 10.1038/bjc.1996.33410.1038/bjc.1996.334 ↗
44. 10.1007/s13277-014-1843-y10.1007/s13277-014-1843-y ↗
45. 10.1007/s00204005053910.1007/s002040050539 ↗
46. 10.1016/j.fct.2007.05.01510.1016/j.fct.2007.05.015 ↗
47. 10.1016/j.bcp.2011.08.01010.1016/j.bcp.2011.08.010 ↗
48. 10.1002/ijc.2045210.1002/ijc.20452 ↗
49. 10.1039/c0ob00640h10.1039/c0ob00640h ↗
50. 10.1016/j.jconrel.2013.06.00910.1016/j.jconrel.2013.06.009 ↗
51. 10.1016/j.jconrel.2009.11.00810.1016/j.jconrel.2009.11.008 ↗
52. 10.1021/nn403606m10.1021/nn403606m ↗